Skip Navigation

Profile

William Jeffrey Petty, M.D.Wake Forest Baptist Health

Doctor Rating

4.8 out of 5

114 Ratings
30 Comments
 

William Jeffrey Petty, M.D.

Associate Professor,

Clinical Interests

Lung Cancer, Thoracic Cancer

Contact Information

Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Media Medical Expert »

Education & Training

  • B.A., Harvey Mudd College, 1994
  • M.D., University of North Carolina School of Medicine, 1998
  • Residency, Duke University Medical Center, 2001
  • Fellowship, Dartmouth Medical School, 2003

Board Certifications

  • American Board of Internal Medicine, Medical Oncology

Memberships

  • Am Assn Of Cancer Research
  • Amer Coll Of Chest Physicians
  • Am Soc of Clinical Oncology

NPI Number

  • 1164406690
William Jeffrey Petty, M.D.

Doctor Rating

4.8 out of 5

114 Ratings
30 Comments
 

William Jeffrey Petty, M.D.

Associate Professor, Hematology & Oncology
Cancer Biology

Research Interests

Lung Neoplasms; Quinazolines; Carcinoma, Non-Small-Cell Lung; Receptor, Epidermal Growth Factor; Neoplasms, Vascular Tissue
More »

Contact Information

Academic: 336-713-4392 | Department: 336-716-4464

Media Medical Expert »

Recent Publications

The impact of hospice services in the care of patients with advanced stage nonsmall cell lung cancer. Duggan KT, Duffus SH, D'Agostino RB Jr, Petty WJ, Streer NP, Stephenson RC.. J Palliat Med. 2017;20(1):29-34.

The effects of smoking status and smoking history on patients with brain metastases from lung cancer. Shenker RF, McTyre ER, Ruiz J, Weaver KE, Cramer C, Alphonse-Sullivan NK, Farris M, Petty WJ, Bonomi MR, Watabe K, Laxton AW, Tatter SB, Warren GW, Chan MD.. Cancer Med. 2017;6(5):944-952.

Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, Robinson M, Bitting RL, Thomas A, Alistar AT, Desnoyers RJ, Goodman M, Albright C, Porosnicu M, Vatca M, Qasem SA, DeYoung B, Kytola V, Nykter M, Chen K, Levine EA, Staren ED,.. J Hematol Oncol. 2017;10(1):100.

Image guided radiation therapy may result in improved local control in locally advanced lung cancer patients. Kilburn JM, Soike MH, Lucas JT, Ayala-Peacock D, Blackstock W, Isom S, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ.. Pract Radiat Oncol. 2016;6(3):e73-e80.

Is a clinical target volume (CTV) necessary in the treatment of lung cancer in the modern era combining 4-D imaging and image-guided radiotherapy (IGRT)?. Kilburn JM, Lucas JT, Soike MH, Ayala-Peacock DN, Blackstock AW, Hinson WH, Munley MT, Petty WJ, Urbanic JJ.. Cureus. 2016;8(1):e466.

A phase II clinical trial of CPI-613 in patients with relapsed or refractory small cell lung carcinoma. Lycan TW, Pardee TS, Petty WJ, Bonomi M, Alistar A, Lamar ZS, Isom S, Chan MD, Miller AA, Ruiz J.. PLoS One. 2016;11(10):e0164244.

Regulation of brachyury by fibroblast growth factor receptor 1 in lung cancer. Hu Y, Feng X, Mintz A, Jeffrey Petty W, Hsu W.. Oncotarget. 2016;7(52):87124-35.

Phase II trial of angiotensin-(1-7) for the treatment of patients with metastatic sarcoma. Savage PD, Lovato J, Brosnihan KB, Miller AA, Petty WJ.. Sarcoma. 2016;2016():4592768.

Hemolytic anemia in two patients with glioblastoma multiforme: a possible interaction between vorinostat and dapsone. Lewis JA, Petty WJ, Harmon M, Peacock JE, Valente K, Owen J, Pirmohamed M, Lesser GJ.. J Oncol Pharm Pract. 2015;21(3):220-223.

Low-dose CT lung cancer screening practices and attitudes among primary care providers at an academic medical center. Lewis JA, Petty WJ, Tooze JA, Miller DP, Chiles C, Miller AA, Bellinger C, Weaver KE.. Cancer Epidemiol Biomarkers Prev. 2015;24(4):664-670.

Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer? [editorial]. Ruiz J, Petty WJ.. Ann Transl Med. 2015;3(3):31.

Clinical implications of RAR-beta methylation in cancer tissue and peripheral blood leukocytes of patients with lung cancer [abstract]. Ansley KC, Dotson T, Hawkins G, Petty WJ.. Int J Mol Med. 2015;36(Suppl 1):S103.

Robotic thoracic surgery for elderly patients with non-small cell lung cancer [abstract]. Hughes RT, Dipasquale VM, Grant SC, Lally BE, Petty WJ, Proto A, Wudel LJ.. J Thorac Oncol. 2015;10(9 Suppl 2):S561.

Molecular subtyping in advanced non-small cell lung cancer, a minimally invasive strategy with small volume fine needle aspirates [abstract]. Hansen K, Miller L, Dotson T, Bellinger C, Parks G, Cappellari J, Clark H, Howard C, Bolemon B, Petty WJ, Craddock L, Ruiz J.. J Thorac Oncol. 2015;10(9 Suppl 2):S701.

Nodal staging via robotic-assisted thoracic surgery for clinical stage I non-small cell lung cancer [abstract]. Dipasquale VM, Hughes RT, Grant S, Lally BE, Petty WJ, Proto A, Wudel LJ.. J Thorac Oncol. 2015;10(9 Suppl 2):S333.

Growing a thoracic oncology program [abstract]. Bellinger CR, Hovda J, Petty WJ, Ruiz J, Dotson TL, Wudel LJ.. Am J Respir Crit Care Med. 2015;191():A5086.

Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer. Kilburn JM, Lester SC, Lucas JT Jr, Soike MH, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ.. J Thorac Oncol. 2014;9(4):572-576.

Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Kilburn JM, Kuremsky JG, Blackstock AW, Munley MT, Kearns WT, Hinson WH, Lovato JF, Miller AA, Petty WJ, Urbanic JJ.. Radiother Oncol. 2014;110(3):505-510.

Which lung tumors shrink during fractionated radiation and how does this influence outcome?: Appropriately selecting tumor and treatment characteristics for adaptive radiation therapy protocols [abstract]. Kilburn JM, Lucas JT, Soike MH, Ayala-Peacock D, Kuremsy JG, Blackstock A, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S641-S642.

An evaluation of toxicity using accumulated total dose based on EQD2 for thoracic reirradiation incorporating at least 1 course of SBRT [abstract]. Lester SC, Kilburn JM, Lucas JT, Soike MH, Blackstock AW, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S640-S641.

Low-dose CT lung cancer screening practices and attitudes among primary care providers at an academic medical center [abstract]. Lewis J, Petty WJ, Tooze JA, Miller DP, Chiles C, Miller AA, Weaver KE.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 5):S7-S8.

Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer. Petty WJ, Laudadio J, Brautnick L, Lovato J, Dotson T, Streer NP, Weaver KE, Miller AA.. Int J Oncol. 2013;43(6):2057-2063.

Stereotactic body radiation therapy (SBRT) and image guided accelerated hypofractionated radiation therapy (IGAHRT) for the treatment of oligometastatic cancers [abstract]. Ayala-Peacock DN, Blackstock AW, Kearns WT, Hinson WH, Munley MT, Miller AA, Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S567-S568.

Is a clinical target volume (CTV) necessary in treatment of thoracic malignancies treated in the modern era combining 4-D imaging and image guided radiation therapy (IGRT)? [abstract]. Kilburn JM, Lucas JT, Soike MH, Ayala-Peacock D, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S549.

Multiple courses of thoracic radiation therapy (XRT) using stereotactic body radiation therapy (SBRT) as the first or second course of treatment for tumors outside the original high-dose region [abstract]. Kilburn JM, Lester SC, Lucas JT, Blackstock AW, Kearns WT, Hinson WH, Munley MT, Miller AA, Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S36.

Salvage radiation for mediastinal relapse after treatment with accelerated hypofractionated radiation therapy (AHRT) or stereotactic body radiation therapy (SBRT) for stage I/II NSCLC [abstract]. Lester SC, Kilburn JM, Lucas JT, Munley MT, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S543-S544.

Image guided radiation therapy results in mproved local control in lung cancer patients treated with fractionated radiation therapy for stage IIB-IIIB disease [abstract]. Soike M, Kilburn JM, Lucas JT, Ayala-Peacock D, Blackstock AW, Kearns WT, Hinson WH, Miller AT [sic] [Miller AA], Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S547-S548.

Tumor histology predicts patterns of failure and survival in patients with brain metastases from lung cancer treated with gamma knife radiosurgery. Kuremsky JG, Urbanic JJ, Petty WJ, Lovato JF, Bourland JD, Tatter SB, Ellis TL [deceased], McMullen KP, Shaw EG, Chan MD.. Neurosurgery. 2013;73(4):641-647.

Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1alpha in vascular sarcomas. Petty WJ, Aklilu M, Varela VA, Lovato J, Savage PD, Miller AA.. BMC Cancer. 2012;12():404.

Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. Socinski MA, Stinchcombe TE, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Khandani A, Morris DE.. J Clin Oncol. 2012;30(32):3953-3959.

Thoracic reirradiation in patients with stereotactic body radiation therapy (SBRT) as first or second course of treatment [abstract]. Kilburn JM, Kuremsky JG, Blackstock AW, Kearns WT, Hampton CJ, Hinson WH, Miller AA, Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S604.

Hypofractionated radiation therapy for stage I and II non-small cell lung cancer [abstract]. Kuremsky JG, Petty WJ, Miller A, Hinson WH, Hampton CJ, Blackstock AW, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S153-S154.

Thoracic re-irradiation in patients with stereotactic body radiotherapy (SBRT) as first or second course of treatment [abstract]. Kilburn KM, Kuremsky JG, Blackstock AW, Kearns WT, Hampton CJ, Hinson WH, Miller AA, Petty WJ, Urbanic JJ.. J Thorac Oncol. 2012;7(9 Suppl 4):S253-S254.

Hypofractionated radiotherapy for stage I and II non-small cell lung cancer [abstract]. Kuremsky JG, Petty WJ, Miller A, HInson WH, Hampton CJ, Blackstock AW, Urbanic JJ.. J Thorac Oncol. 2012;7(9 Suppl 4):S230.

Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC) [abstract]. Stinchcombe T, Socinski MA, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Morris DE.. J Clin Oncol. 2011;29(Suppl):abstr 7016.

Microarray gene expression patterns recapitulated on a clinically tractable diagnostic platform using breast and lung cancer formalin-fixed paraffin-embedded tissues [abstract]. Ruiz J, Chou J, Geisinger KR, Schoppe CH, Miller AA, Willingham MC, Petty WJ, Bolemon BH, Miller LD.. J Clin Oncol. 2011;29(Suppl):e21027.

Phase II study of dose-dense chemotherapy followed by dose-intense erlotinib for initial treatment of metastatic NSCLC [abstract]. Waller LL, Miller AA, Streer NP, Lovato JF, Petty WJ.. J Clin Oncol. 2011;29(Suppl):abstr 7601.

High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. Petty WJ, Voelzke WR, Urbanic JJ, Varela VA, Waller LL, Swift CB, Graham RM, Memoli VA, Dragnev KH.. Lung Cancer. 2011;74(3):384-391.

A role for angiotensin converting enzyme inhibition in lung cancer chemoprevention [abstract]. Petty WJ, Varela VA, Swift CB, Urbanic JJ.. Int J Mol Med. 2011;28(Suppl 1):S68.

Tumor histology predicts patterns of failure and survival in patients with lung cancer treated with gamma knife radiosurgery [abstract]. Kuremsky JG, Urbanic JJ, Petty WJ, Lovato JF, Bourland JD, Tatter SB, Ellis TL, McMullen KP, Shaw EG, Chan MD.. Int J Radiat Oncol Biol Phys. 2011;81(2 Suppl):S595.

A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. Center B, Petty WJ, Ayala D, Hinson WH, Lovato J, Capellari J [sic] [Cappellari J], Oaks T, Miller AA, Blackstock AW.. J Thorac Oncol. 2010;5(1):69-74.

Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke. Waller LL, Miller AA, Petty WJ.. Lung Cancer. 2010;67(1):12-16.

Effects of continued tobacco use during treatment of lung cancer. Waller LL, Weaver KE, Petty WJ, Miller AA.. Expert Rev Anticancer Ther. 2010;10(10):1569-1575.

Overcoming pharmacokinetic resistance to erlotinib: rationale and preliminary findings from a phase II study [abstract]. Waller LL, Miller AA, Streer NP, McCoy TP, Petty WJ.. J Thorac Oncol. 2010;5(6 Suppl 3):S247-S248.

A novel prognostic transcriptional signature for early stage non-small cell lung cancer [abstract]. Ruiz J, Miller AA, Petty WJ, Chou JW, Miller LD.. J Thorac Oncol. 2010;5(12 Suppl 7):S505.

The tumor tissue renin-angiotensin system as a target for cancer therapy [abstract]. Petty WJ, Miller AA, Aklilu M, McCoy TP, Swift CB, Torti FM.. Int J Mol Med. 2010;26(Suppl 1):S19.

Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. Hughes AN, O'Brien MER, Petty WJ, Chick JB, Rankin E, Woll PJ, Dunlop D, Nicolson M, Boinpally R, Wolf J, et al.. J Clin Oncol. 2009;27(8):1220-1226.

Angiotensin-(1-7) inhibits triple negative tumor growth through the inhibition of angiogenesis and a reduction in placental growth factor PIGF [abstract]. Soto-Pantoja DR, Petty WJ, Gallagher PE, Tallant EA.. Cancer Res. 2009;69(2 Suppl):103S.

Incorporation of bevacizumab (B) and erlotinib (Er) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC) [abstract]. Socinski MA, Stinchcombe TE, Halle JS, Moore DT, Petty WJ, Blackstock AW, Gettinger SN, Decker RH, Khandani AH, Morris DE.. J Thorac Oncol. 2009;4(9 Suppl 1):S372-S373.

Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM.. Clin Cancer Res. 2009;15(23):7398-7404.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Associate Professor, Hematology & Oncology

Clinical Interests

Lung Cancer, Thoracic Cancer
William Jeffrey Petty, M.D.

William Jeffrey Petty, M.D.

Associate Professor, Hematology & Oncology
Cancer Biology

Doctor Rating

4.8 out of 5

William Jeffrey Petty, M.D.114 Ratings
30 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.9
CP efforts to include in decisions
4.8
CP explanations of prob/condition
4.8
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.9
Likelihood of recommending CP
4.8
Patients' confidence in CP
4.8
Time CP spent with patient
4.8
Wait time at clinic
4.2



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

10/17/2017

Very good.

9/12/2017

Very good experience

9/9/2017

The care provider is very good to me and my family at all terms.

9/7/2017

Dr. Petty is a super doctor!

8/31/2017

The entire experience at Wake Forest Baptist Health exceeded my expectations.

8/29/2017

Dr Ghandi and Dr Petty are both excellent doctors. They are very thorough and are very good doctors.

8/7/2017

VERY GOOD!!!!

8/1/2017

Best Doctor in NC

7/16/2017

Dr. Petty seems to care about my condition and takes time to listen.

7/10/2017

There was nothing more that I could expect from Dr. Petty! He is the best that could have!

6/27/2017

There aren't enough words to describe how great Dr. Petty is, he is thorough, knowledgeable, understanding, and I believe 100% that he has my best interests at heart and is doing every thing he can to help me. I would highly recommend him to my family and friends.

6/13/2017

VERY good experience!

6/11/2017

I will and have recommended this clinic to other people going through what I have. I have told them how great my experience has been at Baptist.

6/3/2017

we feel the best about him & his knowledge about cancer & the treatments that i need to get

5/21/2017

He is the best in Carolina!!!

5/1/2017

*Dr. Petty is a warm caring friendly doctor.

5/1/2017

*Dr. Petty is everything a doctor should be, knowledgeable, kind, caring, friendly, a good listener and willing to go above and beyond PCR his patients. I trust him 100%.

5/1/2017

Excellent!

4/29/2017

Always excellent!

4/28/2017

My visits are always good.

3/30/2017

I really like *Dr.Petty. He really listen.

3/22/2017

Excellent experience!

3/7/2017

Dr. Petty is an excellent physician and he inspires total confidence in the quality of my care and treatment.

2/6/2017

Very good.

1/31/2017

With *Dr. Petty you know he cares, I can usually tell if the news is good/bad by the way he walks in the room I know that he is doing everything in his power to help me, including researching & consulting with others. I feel he is invested 100% in my recovery. He's a +10!

1/27/2017

VERY good!

1/26/2017

*Dr. Petty is a amazing! He is always thoughtful, kind, and professional. His overall demeanor puts me at ease!

1/25/2017

I have complete confidence in Dr. Petty. I truly believe that his decisions are based on what is best for me. I believe that he cares about my health and truly wants to cure me. His care and concern is far more than most doctors have for their patients.

1/23/2017

Dr. Petty is the greatest. I am very fortunate to have him as my physician.

12/13/2016

Wonderful!

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Six Wake Forest Baptist Specialties Earn U.S. News RankingsComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsMagnet Hospital RecognitionJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.